You just read:

BerGenBio Presents New Phase II Clinical Data That Bemcentinib in Combination With Low Dose Chemotherapy Improves Efficacy and Duration of Survival in Elderly AML Patients at ASCO 2019

News provided by

BerGenBio ASA

03 Jun, 2019, 14:09 BST